The Alsatian Biosynex is considering the acquisition of the American Chembio Diagnostics – Le Journal des Entreprises

The Biosynex group never stops expanding. The Bas-Rhin manufacturer and distributor of medical devices and rapid detection tests for infectious diseases (329 employees, 2021 turnover: €382.70 million) has announced its intention to acquire the American company Chembio Diagnostics. Based in New York State, it develops infectious disease tests covering sexually transmitted infections, respiratory viruses, fever and tropical diseases. For Biosynex, the transaction concerns the acquisition of 100% of Chembio and its German, Brazilian and Malaysian subsidiaries. The transaction is expected to be finalized in the first half of 2023. The Alsatian biotech is thus preparing to expand its portfolio of offers and products after the acquisition of several other companies in recent months, including the Toulouse start-up Doc2U.